(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...

The Oliver Patch Project was born. Three years after launching, the charity has provided more than 1,600 children from ...

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's ...

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.

Ask the publishers to restore access to 500,000+ books. A line drawing of the Internet Archive headquarters building façade. An illustration of a heart shape "Donate to the archive" An illustration of ...

The cell-based assays market is expected to grow from USD 17.3 billion in 2024 to USD 24.3 billion by 2029, reflecting a ...

VolitionRx Limited ("Volition"), a multi-national epigenetics company, hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some of the world's leading experts in ...

Data from the study showed that the drug reduced the risk of disease progression or death by nearly half when compared to Keytruda. This data conforms with the initial results reported by SMMT in ...